Description
HMG (Human Menopausal Gonadotropin, also menotropin) is a compound traditionally extracted from the urine of postmenopausal women. In modern setups it is available in synthetic or recombinant form. In contrast to HCG (which shows primarily LH activity), HMG contains both FSH and LH activity in a defined ratio (typically 1:1 in 75iu per vial).
In the research context of the HPG axis (hypothalamic-pituitary-gonadal), HMG is a central tool for studies aiming to simultaneously address both gonadotropin pathways. FSH activity stimulates follicular development in ovaries and Sertoli cell function in testes in preclinical models. LH activity addresses theca and Leydig cell steroidogenesis. This dual activity makes HMG a distinct research tool.
The combination is mechanistically sensible because both gametogenesis and steroid hormone secretion in the reproductive axis depend on both gonadotropins. Studies that only address one component (e.g., HCG only) provide incomplete data for comprehensive HPG research.
In research setups, HMG is typically used subcutaneously or intramuscularly in preclinical models. The half-life is in the range of several hours, allowing daily to every-other-day application intervals.
HMG is available in 75iu vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
HMG is established as a gonadotropin in research literature, but with its dual FSH and LH activity it intervenes broadly in the reproductive hormone axis.
Observed in research and user reports:
- Hormone axis intervention: the combined FSH and LH stimulation addresses both gametogenesis and steroidogenesis. In preclinical models this can shift the endogenous regulation of the HPG axis.
- Estrogenic effects: as with other gonadotropins, increased steroid synthesis can lead to elevated estradiol and thus to estrogen-mediated effects such as water retention.
- Injection site: redness, pressure or transient irritation at the injection site is among the most common observations, particularly with subcutaneous use.
- No long-term data: robust human studies on longer-term non-clinical use do not exist. The profile rests on clinical fertility data and animal models.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Historical perspectives in gonadotrophin therapy - Human Reproduction Update 2004: Historical review of gonadotrophin research, from the first extracts from pituitaries and urine to today’s highly purified and recombinant preparations.
- Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial - Human Reproduction 2006: Randomized trial in 731 women undergoing IVF: highly purified hMG was non-inferior to recombinant FSH in ongoing pregnancy rate (27% versus 22%), with fewer oocytes retrieved and a different endocrine profile.
- Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles - Cochrane Database of Systematic Reviews 2011: Cochrane review of 42 trials with 9606 couples: no statistically significant difference in live birth rate was found between recombinant FSH and urinary gonadotrophins such as hMG.
- Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome - Journal of Clinical Endocrinology & Metabolism 2009: Analysis of 75 gonadotropin-deficient men on gonadotropin therapy: first sperm appeared after a median of 7.1 months, 38 men became fathers. Larger testis volume predicted a faster response.
